Inventiva S.A. (EPA:IVA)
France · Delayed Price · Currency is EUR 4.705
-0.045 (-0.95%)
Apr 1, 2026, 12:24 PM CET
Inventiva Revenue
In the year 2025, Inventiva had annual revenue of 4.48M EUR, down -51.26%. Inventiva had revenue of 29.00K in the half year ending December 31, 2025, a decrease of -99.81%.
Revenue
4.48M
Revenue Growth
-51.26%
P/S Ratio
114.48
Revenue / Employee
94.36K
Employees
84
Market Cap
907.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.48M | -4.72M | -51.26% |
| Dec 31, 2024 | 9.20M | -8.28M | -47.37% |
| Dec 31, 2023 | 17.48M | 5.30M | 43.50% |
| Dec 31, 2022 | 12.18M | 7.99M | 190.39% |
| Dec 31, 2021 | 4.19M | 3.82M | 1,027.42% |
| Dec 31, 2020 | 372.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 174.66M |
| Cellectis | 67.79M |
| Genfit | 45.13M |
| MedinCell | 32.44M |
| Nanobiotix | 10.16M |
| Transgene | 7.21M |
| Sensorion | 5.81M |
| DBV Technologies | 4.80M |
Inventiva News
- 14 hours ago - Inventiva S.A. (IVA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Inventiva reports 2025 full year results and provides a business update - GlobeNewsWire
- 8 days ago - Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results - GlobeNewsWire
- 12 days ago - Truist Securities Initiates Coverage on Inventiva (IVA) with a "Buy" Rating | IVA ... - GuruFocus
- 20 days ago - Inventiva S.A. (IVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Inventiva reports preliminary 2025¹ fiscal year financial results - GlobeNewsWire
- 7 weeks ago - Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 2 months ago - Biotech Inventiva's 50% surge shows investor optimism over liver disease drug - Reuters